CR20210221A - Derivados de azitromicina y roxitromicina como fármacos senolíticos - Google Patents
Derivados de azitromicina y roxitromicina como fármacos senolíticosInfo
- Publication number
- CR20210221A CR20210221A CR20210221A CR20210221A CR20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A CR 20210221 A CR20210221 A CR 20210221A
- Authority
- CR
- Costa Rica
- Prior art keywords
- azithromycin
- senolytic
- roxithromycin
- activity
- showed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Esta descripción expone el uso de azitromicina,roxitromicina y teli tromicina, inclusive derivados de los mismos,como fármacos senolíticos. La BrdU se usó para inducir la senescencia en un modelo de líneas de células fibroblastos humanas. También se dan a conocer métodos para seleccionar compuestos por la actividad senolítica. El ensayo de SRB se usó para medir la viabilidad celular a través del contenido de proteínas. Se descubrió que la azitromicina, la roxitromicina y latelitromicina, productos farmacéuticos aprobados clínicamente, son fármacos senolíticos. Sin embargo, el compuesto precursor relacionado estrechamente, eritromicina, no mostró actividad senolítica. La azitromicina indujo considerablemente tanto glicólisis aeróbica como autofagia en fibroblastos humanos, pero mostró efectos bifásicos que incluían sobre las tasas de consumo de oxígeno mitocondrial con actividad inhibitoria a 50 µM y actividad estimuladora a 100 µM. El sistema de ensayo en tiempo real xCELLigenceMR mostró que la azitromicina focaliza preferentemente las células senescentes, eliminando aproximadamente 97% (casi una reducción de 25 veces en las células senescentes).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740137P | 2018-10-02 | 2018-10-02 | |
| US201862750559P | 2018-10-25 | 2018-10-25 | |
| US201962788187P | 2019-01-04 | 2019-01-04 | |
| PCT/US2019/054231 WO2020072598A1 (en) | 2018-10-02 | 2019-10-02 | Azithromycin and roxithromycin derivatives as senolytic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210221A true CR20210221A (es) | 2021-06-24 |
Family
ID=70054763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210221A CR20210221A (es) | 2018-10-02 | 2019-10-02 | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11957700B2 (es) |
| EP (1) | EP3860616A4 (es) |
| JP (1) | JP2022504204A (es) |
| KR (1) | KR20210072026A (es) |
| CN (1) | CN113164504A (es) |
| AU (1) | AU2019353002A1 (es) |
| BR (1) | BR112021006423A2 (es) |
| CA (1) | CA3114888A1 (es) |
| CL (1) | CL2021000825A1 (es) |
| CO (1) | CO2021004427A2 (es) |
| CR (1) | CR20210221A (es) |
| CU (1) | CU20210024A7 (es) |
| DO (1) | DOP2021000056A (es) |
| EC (1) | ECSP21029576A (es) |
| IL (1) | IL281879A (es) |
| MX (1) | MX2021003808A (es) |
| PE (1) | PE20211006A1 (es) |
| PH (1) | PH12021550719A1 (es) |
| SG (1) | SG11202103293UA (es) |
| WO (1) | WO2020072598A1 (es) |
| ZA (1) | ZA202102157B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005311A (es) * | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
| WO2023085787A1 (ko) * | 2021-11-10 | 2023-05-19 | 주식회사 라이프신약 | 노화세포 제거용 조성물 및 이의 용도 |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| CN102816194A (zh) | 2004-02-27 | 2012-12-12 | 瑞伯-X医药品有限公司 | 大环化合物以及其制作和使用方法 |
| US20100099634A1 (en) * | 2006-12-12 | 2010-04-22 | Zambon S.P.A | Macrolide compounds endowed with antiinflammatory activity |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| US9775855B2 (en) * | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
| KR101435717B1 (ko) * | 2012-09-06 | 2014-09-01 | 영남대학교 산학협력단 | 퀘세틴-3-Ｏ-β-Ｄ-글루쿠로니드를 유효성분으로 함유하는 세포 노화 억제용 조성물 |
| WO2016118859A1 (en) * | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising flip |
| AU2018205629A1 (en) * | 2017-01-03 | 2019-07-11 | Bioatla Llc | Protein therapeutics for treatment of senescent cells |
| JP7104134B2 (ja) | 2017-03-15 | 2022-07-20 | ルネラ・バイオテック・インコーポレーテッド | ミトリボシン：癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬 |
| US11427606B2 (en) * | 2017-04-20 | 2022-08-30 | Rising Tide Foundation | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
| EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| BR112019024264A2 (pt) | 2017-05-19 | 2020-06-02 | Lunella Biotech, Inc. | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| MX2019014806A (es) | 2017-06-26 | 2020-02-10 | Lunella Biotech Inc | Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas. |
| EP3700512A4 (en) | 2017-10-24 | 2021-08-11 | Lunella Biotech, Inc. | MITOFLAVOSCINE: TARGETING FLAVINAL ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL BREATHING |
| MX2020005311A (es) | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
| EP3717015A4 (en) | 2017-12-01 | 2021-07-28 | Lunella Biotech, Inc. | REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| SG11202106532WA (en) | 2018-12-17 | 2021-07-29 | Lunella Biotech Inc | Triple combination therapies for anti-aging |
-
2019
- 2019-10-02 CR CR20210221A patent/CR20210221A/es unknown
- 2019-10-02 AU AU2019353002A patent/AU2019353002A1/en active Pending
- 2019-10-02 SG SG11202103293UA patent/SG11202103293UA/en unknown
- 2019-10-02 WO PCT/US2019/054231 patent/WO2020072598A1/en active Application Filing
- 2019-10-02 CU CU2021000024A patent/CU20210024A7/es unknown
- 2019-10-02 MX MX2021003808A patent/MX2021003808A/es unknown
- 2019-10-02 US US17/282,212 patent/US11957700B2/en active Active
- 2019-10-02 CA CA3114888A patent/CA3114888A1/en active Pending
- 2019-10-02 KR KR1020217012994A patent/KR20210072026A/ko unknown
- 2019-10-02 JP JP2021518508A patent/JP2022504204A/ja active Pending
- 2019-10-02 BR BR112021006423A patent/BR112021006423A2/pt unknown
- 2019-10-02 CN CN201980079188.4A patent/CN113164504A/zh active Pending
- 2019-10-02 EP EP19869744.3A patent/EP3860616A4/en active Pending
- 2019-10-02 PE PE2021000425A patent/PE20211006A1/es unknown
-
2021
- 2021-03-29 IL IL281879A patent/IL281879A/en unknown
- 2021-03-30 ZA ZA2021/02157A patent/ZA202102157B/en unknown
- 2021-03-31 CL CL2021000825A patent/CL2021000825A1/es unknown
- 2021-03-31 PH PH12021550719A patent/PH12021550719A1/en unknown
- 2021-03-31 DO DO2021000056A patent/DOP2021000056A/es unknown
- 2021-04-09 CO CONC2021/0004427A patent/CO2021004427A2/es unknown
- 2021-04-26 EC ECSENADI202129576A patent/ECSP21029576A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202103293UA (en) | 2021-04-29 |
| US11957700B2 (en) | 2024-04-16 |
| EP3860616A1 (en) | 2021-08-11 |
| CL2021000825A1 (es) | 2021-10-22 |
| CO2021004427A2 (es) | 2021-04-30 |
| BR112021006423A2 (pt) | 2021-07-06 |
| ZA202102157B (en) | 2022-09-28 |
| WO2020072598A1 (en) | 2020-04-09 |
| PH12021550719A1 (en) | 2021-12-06 |
| ECSP21029576A (es) | 2021-05-31 |
| US20210275560A1 (en) | 2021-09-09 |
| JP2022504204A (ja) | 2022-01-13 |
| PE20211006A1 (es) | 2021-06-01 |
| DOP2021000056A (es) | 2021-06-30 |
| KR20210072026A (ko) | 2021-06-16 |
| IL281879A (en) | 2021-05-31 |
| CA3114888A1 (en) | 2020-04-09 |
| AU2019353002A1 (en) | 2021-05-06 |
| MX2021003808A (es) | 2021-05-27 |
| EP3860616A4 (en) | 2022-07-06 |
| CN113164504A (zh) | 2021-07-23 |
| CU20210024A7 (es) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550719A1 (en) | Azithromycin and roxithromycin derivatives as senolytic drugs | |
| Wang et al. | Glycine stimulates protein synthesis and inhibits oxidative stress in pig small intestinal epithelial cells | |
| Patil et al. | Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter | |
| Meca et al. | Comparative cytotoxicity study of enniatins A, A1, A2, B, B1, B4 and J3 on Caco-2 cells, Hep-G2 and HT-29 | |
| Baynosa et al. | The effect of hyperbaric oxygen on nitric oxide synthase activity and expression in ischemia-reperfusion injury | |
| Nelson et al. | VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENTNAïVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS: LB-14 | |
| Zou et al. | Cordyceps sinensis oral liquid prolongs the lifespan of the fruit fly, Drosophila melanogaster, by inhibiting oxidative stress | |
| Molinaro et al. | D-aspartate activates mGlu receptors coupled to polyphosphoinositide hydrolysis in neonate rat brain slices | |
| Ziolkowska et al. | Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor | |
| Rong et al. | Sirt 1 activator attenuates the bleomycin-induced lung fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). | |
| Cavalcante et al. | Neuromuscular effects of venoms and crotoxin-like proteins from Crotalus durissus ruruima and Crotalus durissus cumanensis | |
| Reynolds et al. | Inhibition of induction of rat liver tyrosine aminotransferase by D-galactosamine: role of uridine triphosphate | |
| MXPA05011435A (es) | 5-hidroxiindoles con grupos de n-oxido y su uso como inhibidores de fosfodiesterasa 4. | |
| BRPI0409790A (pt) | 7-azaindóis e seu uso como terapêuticos | |
| Ribeiro | Chemoreceptors in respiratory control | |
| Abad | Chemical constituents, antibacterial properties, and cytotoxic activities of Pycnoporus coccineus | |
| 李溱 | Comprehensive Review on “Critical Period Hypothesis” and the Role of Age in Second Language Learning | |
| Kumari | Recurrent pyoderma with Malassezia and hyperadrenocorticism in a dog | |
| Kolesnichenko et al. | Potentiating Interaction of Ethoxydol and Rosuvastatin in an Experimental Model of Langendorf-isolated Rat Heart Total Ischemia-reperfusion | |
| Takizawa et al. | Direct Sensing of Lipopolysaccharide Limits Hematopoietic Stem Cell Selfrenewal Via TLR4-TRIF-ROS-p38 Pathway | |
| A Esmaial et al. | Study of Cholinesterase Activity in Adult Ewes Treated by the Anthelmintic Drug Levamisole | |
| Soldatov | Potentiating Interaction of Ethoxydol and Rosuvastatin in an Experimental Model of Langendorf-isolated Rat Heart Total Ischemia-reperfusion | |
| Karppinen | Search for biologically active compounds in AndoSanTM, a medicinal mushroom extract | |
| Qiong et al. | Influence of MSAA3 protein fragment and modified peptide thereof on the MUC3 expression of HT29 cells | |
| Miglio et al. | Linagliptin decreases the growth of immortalised human podocytes through the SDF-1-CXCR4/CXCR7 axis |